Immunotherapy combo before kidney surgery shows promise in small trial
NCT ID NCT04028245
First seen Apr 22, 2026 · Last updated May 25, 2026 · Updated 4 times
Summary
This early-phase study tested two immunotherapy drugs (spartalizumab and canakinumab) given before surgery to 17 people with localized kidney cancer. The main goal was to see if the combination was safe and did not delay surgery. Researchers also looked at how the drugs affected the immune system and tumor size. The trial was not designed to cure the disease, but to gather safety and immune data.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, RENAL CELL are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Columbia University Irving Medical Center
New York, New York, 10032, United States
Conditions
Explore the condition pages connected to this study.